Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 93 of the 100 references it cites were found in a registry or an index; 60 of the 81 sources its claims cite were checked for support.

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Open access

Published version of a preprint

Abstract

KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018.

Overview

CoChat Summary

TL;DR

This multimodal study defines heterogeneous genetic and non-genetic resistance mechanisms to mutant-selective KRAS inhibition in pancreatic ductal adenocarcinoma (PDAC), using patient ctDNA and preclinical models. It finds recurrent RTK–RAS/PI3K pathway alterations, cell-cycle/efflux amplifications, and a drug-resistant partial EMT cell state, supporting combination strategies with chemotherapy or RTK/CLDN18.2-directed agents.

Key findings

  • In 22 patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, 18/22 (81%) had PR/SD and acquired resistance, 4/22 had primary resistance, and putative genetic resistance mechanisms were identified in 9/22 (41%); across an aggregate KRASG12C cohort, genetic mechanisms were found in 51% of NSCLC, 52% of CRC, 46% of PDAC, and 75% of other GI cancers, while no putative genetic mechanism was identified in 54% of PDAC, 49% of NSCLC, and 48% of CRC.
  • In preclinical models, MRTX1133 selectively inhibited KRASG12D-mutant cells across 877 PRISM cell lines; among 46 KRASG12D lines, 22 were sensitive and 24 resistant by AUC, with resistance associated with EMT, RTK–RAS pathway gene copy gains, PI3K–AKT–mTOR activation, and MYC/cell-cycle signatures.
  • In the autochthonous KPC GEMM, MRTX1133 prolonged median survival to 10.7 weeks versus 1 week for vehicle (P = 2.08e–6), with complete responses in 67% (10/15), PRs in 27% (4/15), and primary resistance in 1/15; 55% (6/11) of endpoint MRTX1133-resistant tumors had high-level amplifications including Myc, Kras, Yap1, and Cdk6/Abcb1a/b.
  • Single-nucleus RNA-seq of 68,479 nuclei showed MRTX1133-resistant tumors shifted toward pEMT (60% of nuclei) and mesenchymal (30%) states, and combination MRTX1133 plus gemcitabine/n(ab)-paclitaxel prevented relapse in orthotopic and metastatic models, with no lung metastases in combination-treated mice in the established-metastasis assay.

Methods

  • Patient ctDNA from pretreatment and end-of-therapy plasma was sequenced from patients with KRASG12C-mutant PDAC treated on KRYSTAL-1 (adagrasib) or CodeBreaK100 (sotorasib), plus additional GI cancer samples and previously published KRASG12C inhibitor resistance cohorts.
  • Preclinical profiling included PRISM multiplex cell-line screening (877 lines), KRASG12D-mutant PDAC patient-derived organoids (n = 20), isogenic MRTX1133-resistant cell lines, KPC GEMMs, PDX models, WES, bulk RNA-seq, snRNA-seq, RPPA, RTK arrays, immunoblots, IHC, and multiplex immunofluorescence.
  • Analyses included AUC/dose-response modeling, GSEA, NMF metaprogram identification, inferCNV, pySCENIC regulon analysis, Markov absorption-based cell-state classification, and survival/statistical comparisons as described.

Limitations

  • Stated: human PDAC resistance analysis relied primarily on ctDNA, and the authors note that future biopsies from patients progressing on RAS inhibitors are needed to fully interrogate genetic and non-genetic resistance.
  • Stated: preclinical studies focused on the KRASG12D inhibitor MRTX1133; resistance mechanisms need evaluation with pan-RAS/pan-KRAS inhibitors and drugs of different selectivity/mechanism to define cross-resistance patterns.
  • Evident from the text: the patient cohort is described as rare and limited to 22 PDAC patients, ctDNA-based detection may miss resistance drivers, and some resistant tumors/subclones lacked identifiable genomic drivers, leaving non-genetic mechanisms incompletely resolved.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-24-0177

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Genetic alterations associated with acquired resistance to KRASG12C inhibition in patients with PDAC. A, Variant allele frequencies (VAF) for the indicated genomic variants in pretreatment (PT) and end of therapy (EOT) ctDNA samples across patients with PDAC treated with adagrasib monotherapy on the KRYSTAL-1 trial (patients 4, 6) or sotorasib monotherapy on the CodeBreaK100 trial (patients 11, 13, 21, 22). B, Paired genome-wide copy number profiles from low-pass whole genome sequencing (organized by chromosome and genomic coordinates) from PT and EOT ctDNA samples for patient 4 treated with adagrasib. Gene labels indicate amplified putative drivers of acquired resistance or tumor suppressor genes. C, Co-mutation plot displaying pathogenic and likely pathogenic treatment-emergent variants and genomic amplification of putative drivers of resistance detected in ctDNA samples from PDAC patients with acquired resistance to adagrasib (patients 1–8) or sotorasib (patients 9–22). The best radiographic treatment response is indicated as measured by RECIST criteria. D, Aggregated classification of mechanisms of resistance to KRASG12C inhibition across cancer types. Data include patients from this study and previously published studies (Supplementary Table S2; Supplementary Fig. S1G).
Figure 1. Genetic alterations associated with acquired resistance to KRASG12C inhibition in patients with PDAC. A, Variant allele frequencies (VAF) for the indicated genomic variants in pretreatment (PT) and end of therapy (EOT) ctDNA samples across patients with PDAC treated with adagrasib monotherapy on the KRYSTAL-1 trial (patients 4, 6) or sotorasib monotherapy on the CodeBreaK100 trial (patients 11, 13, 21, 22). B, Paired genome-wide copy number profiles from low-pass whole genome sequencing (organized by chromosome and genomic coordinates) from PT and EOT ctDNA samples for patient 4 treated with adagrasib. Gene labels indicate amplified putative drivers of acquired resistance or tumor suppressor genes. C, Co-mutation plot displaying pathogenic and likely pathogenic treatment-emergent variants and genomic amplification of putative drivers of resistance detected in ctDNA samples from PDAC patients with acquired resistance to adagrasib (patients 1–8) or sotorasib (patients 9–22). The best radiographic treatment response is indicated as measured by RECIST criteria. D, Aggregated classification of mechanisms of resistance to KRASG12C inhibition across cancer types. Data include patients from this study and previously published studies (Supplementary Table S2; Supplementary Fig. S1G).CC BY-NC-ND · PubMed Central
Figure 2. Multiomic analysis identifies baseline features of response and resistance to KRASG12D inhibition. A, Boxplot representing the response to MRTX1133 plotted as the area under the dose-response curve (AUC) for 877 cell lines evaluated in the PRISM multiplex cell line screening assay. Cell lines are grouped by KRAS genotypes. AUCs were compared between each KRAS genotype relative to KRASG12D. Significance was determined via Kruskal–Wallis test followed by Dunn’s test and adjusted with Benjamini–Hochberg correction. The adjusted P value for each comparison is displayed on top of each group. B, Boxplot depicting the difference in response to MRTX1133 between subsets of resistant and sensitive KRASG12D cell lines. PDAC cell lines are colored in purple. Significance for the AUC comparison between resistant and sensitive subsets was determined by a two-sided Wilcoxon rank-sum test. C, Heatmap depicting differentially expressed features (gene copy number, gene expression, and protein levels) between MRTX1133-resistant and -sensitive KRASG12D PDAC cell lines. Each column represents a feature that is Z-scored across cell lines (rows). D, Volcano plot depicting differential gene copy number analysis between resistant and sensitive KRASG12D PDAC cell lines. The X-axis depicts the mean difference of Log2 copy number ratio calls of each protein-coding gene (relative to ploidy), between resistant and sensitive cell lines. Significance determined by two-sided Student t test. E, Hallmark transcriptional gene sets significantly enriched or depleted between resistant and sensitive KRASG12D PDAC cell lines. The normalized enrichment score from GSEA is shown on the x-axis. F, Volcano plot depicting differentially expressed proteins or phosphorylated proteins between resistant and sensitive KRASG12D PDAC cell lines. RPPA data were obtained from the Cancer Dependency Map. Significance determined by two-sided Student t test. G, MRTX1133 dose-response curves for a 6-day cell-titer-glo 3D assays with KRASG12D-mutant PDAC PDOs. PDO labels are in order of sensitivity, with lower AUC being more sensitive. Points are the mean ± SEM (n = 3 biological replicates per PDO). H, Co-mutation plot of KRASG12D-mutant PDAC PDOs displaying recurrently altered genes and selected putative drivers of baseline resistance to MRTX1133 across the cohort.
Figure 2. Multiomic analysis identifies baseline features of response and resistance to KRASG12D inhibition. A, Boxplot representing the response to MRTX1133 plotted as the area under the dose-response curve (AUC) for 877 cell lines evaluated in the PRISM multiplex cell line screening assay. Cell lines are grouped by KRAS genotypes. AUCs were compared between each KRAS genotype relative to KRASG12D. Significance was determined via Kruskal–Wallis test followed by Dunn’s test and adjusted with Benjamini–Hochberg correction. The adjusted P value for each comparison is displayed on top of each group. B, Boxplot depicting the difference in response to MRTX1133 between subsets of resistant and sensitive KRASG12D cell lines. PDAC cell lines are colored in purple. Significance for the AUC comparison between resistant and sensitive subsets was determined by a two-sided Wilcoxon rank-sum test. C, Heatmap depicting differentially expressed features (gene copy number, gene expression, and protein levels) between MRTX1133-resistant and -sensitive KRASG12D PDAC cell lines. Each column represents a feature that is Z-scored across cell lines (rows). D, Volcano plot depicting differential gene copy number analysis between resistant and sensitive KRASG12D PDAC cell lines. The X-axis depicts the mean difference of Log2 copy number ratio calls of each protein-coding gene (relative to ploidy), between resistant and sensitive cell lines. Significance determined by two-sided Student t test. E, Hallmark transcriptional gene sets significantly enriched or depleted between resistant and sensitive KRASG12D PDAC cell lines. The normalized enrichment score from GSEA is shown on the x-axis. F, Volcano plot depicting differentially expressed proteins or phosphorylated proteins between resistant and sensitive KRASG12D PDAC cell lines. RPPA data were obtained from the Cancer Dependency Map. Significance determined by two-sided Student t test. G, MRTX1133 dose-response curves for a 6-day cell-titer-glo 3D assays with KRASG12D-mutant PDAC PDOs. PDO labels are in order of sensitivity, with lower AUC being more sensitive. Points are the mean ± SEM (n = 3 biological replicates per PDO). H, Co-mutation plot of KRASG12D-mutant PDAC PDOs displaying recurrently altered genes and selected putative drivers of baseline resistance to MRTX1133 across the cohort.CC BY-NC-ND · PubMed Central
Figure 3. CNAs, EMT, and differential RTK signaling drive acquired resistance to KRASG12D inhibition in vitro. A, Experimental workflow used to generate and characterize isogenic models of acquired resistance to MRTX1133. Parental (.P, blue) and resistant (.R, red) cell line labeling is consistent throughout this figure. B, Pairwise comparisons of the AUC for MRTX1133 between parental and derived resistant murine and human cell lines. Significance determined by two-sided Student t test (n = 3 biological replicates per cell line). The P value for each comparison is displayed at the top of each cell line pair. C, MRTX1133 treatment of syngeneic subcutaneous implant models of parental and resistant murine PDAC cell lines in C57BL6/J mice. Points are the mean ± SEM (n = 5 double-flanked mice per cell line). Significance was determined using a two-sided Wilcoxon rank-sum test on AUCs between resistant and parental cell lines. The P value for each comparison is displayed next to each cell line pair. D, Heatmap of copy number profiles at chromosomes 5 and 6, obtained from DNA WES of murine-resistant cell lines. Copy number ratios are calculated relative to each resistant cell line’s matched parental line. Genes are organized by chromosome and genomic coordinates. Amplified/gained putative drivers of resistance to MRTX1133 are labeled. E, Hallmark transcriptional gene sets significantly enriched in resistant (red) compared with matched parental (blue) human and murine cell lines. F, Immunoblots of murine and human isogenic parental/resistant cell line pairs treated with MRTX1133 (100 nmol/L) for the indicated duration. β-actin was used as protein loading control. G, Receptor tyrosine kinase (RTK) arrays of Panc 02.03 parental (.P) and resistant (.R) cell line pair, treated with DMSO or MRTX1133 (100 nmol/L) for the indicated timepoints. RTKs differentially activated across treatment conditions and cell lines are labeled. H, Left, Heatmap depicting the densitometric quantification showing RTKs differentially activated upon 5 or 48 hours of MRTX1133 treatment relative to matched DMSO-treated control. Right, bar plots depicting the relative densitometric difference for each RTK upon MRTX1133 treatment for the indicated timepoints between the resistant and the parental cell lines. Quantification is representative of two independent experiments. I, Dose-response curves based on 5-day cell-titer-glo 2.0 assays for MRTX1133 combination with RTK targeted therapies with the isogenic parental and resistant Panc 02.03 cell lines. Concentrations of the second drug are displayed on the right. TNO-155, allosteric SHP2 inhibitor; erlotinib, EGFR inhibitor; afatinib, multi-targeted inhibitor of EGFR, ERBB2/HER2, and ERBB4. Points are the mean ± SEM (n = 3 biological replicates). J, Average Bliss synergy score for combinations of MRTX1133 with RTK-directed therapies across parental and resistant Panc 02.03 cell lines. Points are the mean ± SEM (n = 3 biological replicates).
Figure 3. CNAs, EMT, and differential RTK signaling drive acquired resistance to KRASG12D inhibition in vitro. A, Experimental workflow used to generate and characterize isogenic models of acquired resistance to MRTX1133. Parental (.P, blue) and resistant (.R, red) cell line labeling is consistent throughout this figure. B, Pairwise comparisons of the AUC for MRTX1133 between parental and derived resistant murine and human cell lines. Significance determined by two-sided Student t test (n = 3 biological replicates per cell line). The P value for each comparison is displayed at the top of each cell line pair. C, MRTX1133 treatment of syngeneic subcutaneous implant models of parental and resistant murine PDAC cell lines in C57BL6/J mice. Points are the mean ± SEM (n = 5 double-flanked mice per cell line). Significance was determined using a two-sided Wilcoxon rank-sum test on AUCs between resistant and parental cell lines. The P value for each comparison is displayed next to each cell line pair. D, Heatmap of copy number profiles at chromosomes 5 and 6, obtained from DNA WES of murine-resistant cell lines. Copy number ratios are calculated relative to each resistant cell line’s matched parental line. Genes are organized by chromosome and genomic coordinates. Amplified/gained putative drivers of resistance to MRTX1133 are labeled. E, Hallmark transcriptional gene sets significantly enriched in resistant (red) compared with matched parental (blue) human and murine cell lines. F, Immunoblots of murine and human isogenic parental/resistant cell line pairs treated with MRTX1133 (100 nmol/L) for the indicated duration. β-actin was used as protein loading control. G, Receptor tyrosine kinase (RTK) arrays of Panc 02.03 parental (.P) and resistant (.R) cell line pair, treated with DMSO or MRTX1133 (100 nmol/L) for the indicated timepoints. RTKs differentially activated across treatment conditions and cell lines are labeled. H, Left, Heatmap depicting the densitometric quantification showing RTKs differentially activated upon 5 or 48 hours of MRTX1133 treatment relative to matched DMSO-treated control. Right, bar plots depicting the relative densitometric difference for each RTK upon MRTX1133 treatment for the indicated timepoints between the resistant and the parental cell lines. Quantification is representative of two independent experiments. I, Dose-response curves based on 5-day cell-titer-glo 2.0 assays for MRTX1133 combination with RTK targeted therapies with the isogenic parental and resistant Panc 02.03 cell lines. Concentrations of the second drug are displayed on the right. TNO-155, allosteric SHP2 inhibitor; erlotinib, EGFR inhibitor; afatinib, multi-targeted inhibitor of EGFR, ERBB2/HER2, and ERBB4. Points are the mean ± SEM (n = 3 biological replicates). J, Average Bliss synergy score for combinations of MRTX1133 with RTK-directed therapies across parental and resistant Panc 02.03 cell lines. Points are the mean ± SEM (n = 3 biological replicates).CC BY-NC-ND · PubMed Central
Figure 4. Heterogeneous genomic amplifications drive resistance to KRASG12D inhibition in the KPC mouse model of PDAC. A, Overview of the KPC GEMM treatment study. Early vehicle- and MRTX1133-treated mice were euthanized after 3 days of treatment, and long-term treated endpoint vehicle and MRTX1133-resistant mice were sacrificed at clinical endpoint. B, Kaplan–Meier survival curves of KPC mice treated until clinical endpoint with the indicated regimens (Vehicle, n = 9; MRTX1133, n = 15). C, Tumor growth kinetics of KPC mice treated until clinical endpoint, as measured by ultrasound, throughout treatment across the indicated treatment/response groups. D, Waterfall plot displaying the maximal tumor response in KPC mice, as measured by the smallest tumor size while on MRTX1133 treatment. E, Chromosomal CN profiles from WES demonstrating regions of amplification from MRTX1133-resistant KPC tumors. Genes are displayed by genomic coordinates. The segmented copy number trend is depicted by the black line and amplified putative drivers of resistance to MRTX1133 are labeled in red, with their genomic coordinates indicated by a red line. F, Left, UMAP embedding of single-nuclei from KPC PDAC tumors and colored by sample ID. Outlined are the four major non-malignant cell populations identified (CAFs, cancer-associated fibroblasts; ECs, endothelial cells; TAMs, tumor-associated macrophages). Right, Sample-wise pie charts displaying malignant cell clonality as determined by inferCNV. G, Heatmaps of single-nucleus CN profiles inferred from snRNA-seq of two MRTX1133-resistant tumors (top: KPC_3600 and bottom: KPC_3323), organized by chromosomes and genomic coordinates (columns). Row splits indicate major subclones identified within each tumor via inferCNV. The top annotation bar indicates the matched genomic reference from WES for the same tumor. Genomic amplifications identified by WES are labeled at the bottom. H, Aggregate representation of putative genomic mechanisms of resistance across MRTX1133-resistant KPC tumors. The inner ring indicates tumors and inferred clonality when available/present from snRNA-seq. The outer ring indicates the presence, distribution, and names of the putative genomic drivers of resistance to MRTX1133 identified via WES and inferCNV. * denotes tumors for which snRNA-seq data are available.
Figure 4. Heterogeneous genomic amplifications drive resistance to KRASG12D inhibition in the KPC mouse model of PDAC. A, Overview of the KPC GEMM treatment study. Early vehicle- and MRTX1133-treated mice were euthanized after 3 days of treatment, and long-term treated endpoint vehicle and MRTX1133-resistant mice were sacrificed at clinical endpoint. B, Kaplan–Meier survival curves of KPC mice treated until clinical endpoint with the indicated regimens (Vehicle, n = 9; MRTX1133, n = 15). C, Tumor growth kinetics of KPC mice treated until clinical endpoint, as measured by ultrasound, throughout treatment across the indicated treatment/response groups. D, Waterfall plot displaying the maximal tumor response in KPC mice, as measured by the smallest tumor size while on MRTX1133 treatment. E, Chromosomal CN profiles from WES demonstrating regions of amplification from MRTX1133-resistant KPC tumors. Genes are displayed by genomic coordinates. The segmented copy number trend is depicted by the black line and amplified putative drivers of resistance to MRTX1133 are labeled in red, with their genomic coordinates indicated by a red line. F, Left, UMAP embedding of single-nuclei from KPC PDAC tumors and colored by sample ID. Outlined are the four major non-malignant cell populations identified (CAFs, cancer-associated fibroblasts; ECs, endothelial cells; TAMs, tumor-associated macrophages). Right, Sample-wise pie charts displaying malignant cell clonality as determined by inferCNV. G, Heatmaps of single-nucleus CN profiles inferred from snRNA-seq of two MRTX1133-resistant tumors (top: KPC_3600 and bottom: KPC_3323), organized by chromosomes and genomic coordinates (columns). Row splits indicate major subclones identified within each tumor via inferCNV. The top annotation bar indicates the matched genomic reference from WES for the same tumor. Genomic amplifications identified by WES are labeled at the bottom. H, Aggregate representation of putative genomic mechanisms of resistance across MRTX1133-resistant KPC tumors. The inner ring indicates tumors and inferred clonality when available/present from snRNA-seq. The outer ring indicates the presence, distribution, and names of the putative genomic drivers of resistance to MRTX1133 identified via WES and inferCNV. * denotes tumors for which snRNA-seq data are available.CC BY-NC-ND · PubMed Central
Figure 5. Malignant cell state evolution along the epithelial–mesenchymal axis during response and resistance to MRTX1133 in vivo. A, Left, Heatmap of pairwise Jaccard similarities between recurrent NMF programs identified across KPC tumors and ordered by hierarchical clustering. Six consensus classifications (metaprograms) are labeled and indicated by squares. Right, Heatmap depicting the top functional annotation for each metaprogram. Significance determined by hypergeometric test and adjusted with Benjamini–Hochberg correction. B, Cell state–centered differential gene expression across the mesenchymal, classical, and pEMT malignant cell populations. Cell state-specific upregulated genes are colored, and subsets are labeled. C, Top enriched Hallmark gene expression signatures across cell state–specific upregulated genes displayed in B. Significance determined by hypergeometric test and adjusted with Benjamini–Hochberg correction. D, Heatmap depicting the top five regulons associated with each metaprogram. The average Pearson’s correlation coefficients are calculated between each regulon activity scores, as inferred by pySCENIC, and metaprogram scores across malignant nuclei. E, Ternary plot displaying the cell state classification probability of each nucleus across the classical-pEMT-mesenchymal tripartite framework, as calculated by a Markov absorption-based classifier (“Methods”). The coloration gradient is proportional to the fraction of nuclei from a given treatment group found in the same neighborhood. F, Top, Multiplex immunofluorescence (mIF) of PDAC areas from four representative tumors with overlaid DAPI (nucleus), pan-cytokeratin (panCK, tumor), and Claudin-18.2 immunostaining. The scale bar represents 50 μm. Bottom left, Tumor-wise Claudin-18.2 fluorescence classification across treatment groups via mIF. Bottom right, Treatment-wise classification of Claudin-18.2 expression via mIF. G, Improved responses observed in basal-like compared with classical human PDAC PDX models. Top, Boxplot depicting the basal-like/classical difference score for each PDX model following 3-day treatment with the indicated regimen. Significance for the vehicle vs. MRTX1133 comparison was determined by two-sided Student t test. The P value for the treatment comparison is displayed at the top of each PDX model’s track and only significant comparisons are displayed. Middle, Barplot depicting the tumor volume change at endpoint after MRTX1133 treatment, compared to baseline. Significance between basal-like and classical models determined by two-sided Student t test. Bottom, Co-mutation plot of recurrently mutated genes in PDAC for each PDX model. H, Violin plot depicting the pEMT scores from snRNA-seq across nuclei from MRTX1133-resistant tumors, divided according to subclones as determined by inferred copy number profiles. Genomic amplifications identified by WES and inferCNV are denoted. Scores are compared between subclones within the same tumors. Significance was determined between clones from the same tumor by a two-sided Wilcoxon rank-sum test and adjusted with Benjamini–Hochberg correction. The P values are displayed on top of each clone pairs.
Figure 5. Malignant cell state evolution along the epithelial–mesenchymal axis during response and resistance to MRTX1133 in vivo. A, Left, Heatmap of pairwise Jaccard similarities between recurrent NMF programs identified across KPC tumors and ordered by hierarchical clustering. Six consensus classifications (metaprograms) are labeled and indicated by squares. Right, Heatmap depicting the top functional annotation for each metaprogram. Significance determined by hypergeometric test and adjusted with Benjamini–Hochberg correction. B, Cell state–centered differential gene expression across the mesenchymal, classical, and pEMT malignant cell populations. Cell state-specific upregulated genes are colored, and subsets are labeled. C, Top enriched Hallmark gene expression signatures across cell state–specific upregulated genes displayed in B. Significance determined by hypergeometric test and adjusted with Benjamini–Hochberg correction. D, Heatmap depicting the top five regulons associated with each metaprogram. The average Pearson’s correlation coefficients are calculated between each regulon activity scores, as inferred by pySCENIC, and metaprogram scores across malignant nuclei. E, Ternary plot displaying the cell state classification probability of each nucleus across the classical-pEMT-mesenchymal tripartite framework, as calculated by a Markov absorption-based classifier (“Methods”). The coloration gradient is proportional to the fraction of nuclei from a given treatment group found in the same neighborhood. F, Top, Multiplex immunofluorescence (mIF) of PDAC areas from four representative tumors with overlaid DAPI (nucleus), pan-cytokeratin (panCK, tumor), and Claudin-18.2 immunostaining. The scale bar represents 50 μm. Bottom left, Tumor-wise Claudin-18.2 fluorescence classification across treatment groups via mIF. Bottom right, Treatment-wise classification of Claudin-18.2 expression via mIF. G, Improved responses observed in basal-like compared with classical human PDAC PDX models. Top, Boxplot depicting the basal-like/classical difference score for each PDX model following 3-day treatment with the indicated regimen. Significance for the vehicle vs. MRTX1133 comparison was determined by two-sided Student t test. The P value for the treatment comparison is displayed at the top of each PDX model’s track and only significant comparisons are displayed. Middle, Barplot depicting the tumor volume change at endpoint after MRTX1133 treatment, compared to baseline. Significance between basal-like and classical models determined by two-sided Student t test. Bottom, Co-mutation plot of recurrently mutated genes in PDAC for each PDX model. H, Violin plot depicting the pEMT scores from snRNA-seq across nuclei from MRTX1133-resistant tumors, divided according to subclones as determined by inferred copy number profiles. Genomic amplifications identified by WES and inferCNV are denoted. Scores are compared between subclones within the same tumors. Significance was determined between clones from the same tumor by a two-sided Wilcoxon rank-sum test and adjusted with Benjamini–Hochberg correction. The P values are displayed on top of each clone pairs.CC BY-NC-ND · PubMed Central
Figure 6. Enhanced efficacy of combination treatment with KrasG12D inhibition and chemotherapy in primary and metastatic PDAC. A, Tumor growth kinetics (as measured by ultrasound) of 6694C2 orthotopic pancreatic tumors in C57BL6/J mice treated with the indicated regimens. Comparisons have been done at the endpoint of vehicle treated mice against all other arms (day 28, timepoint 1); and at day 52 for MRTX1133 and MRTX1133/GnP compared to GnP alone (timepoint 2). Significance determined with two-way ANOVA with the Šidák multiple comparisons test. The adjusted P values for each timepoint and comparison is displayed on the right. B, Immunoblots of the 6694C2 and 6694-LM cell lines treated for 24 hours with the indicated doses of MRTX1133. GAPDH was used as protein loading control. C, MRTX1133 dose-response curves for 6694C2 and 6694C2-LM cell lines treated with increasing concentration of MRTX1133 for 5 days. Points are the mean ± SEM of three biological replicates. Significance determined by two-sided Student t test between AUCs from three biological replicates from each cell line. D, Vehicle and MRTX1133 treatment of animals bearing syngeneic subcutaneous double flank tumors of 6694C2 or 6694C2-LM. Points are the mean ± SEM (n = 5 double flanked mice per cell line and treatment). Significance determined by Brown–Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test. E, Overview of the metastatic model. Subcutaneous 6694C2-LM tumors are surgically resected, and mice are monitored for lung metastasis. Adjuvant treatment schedule is shown, with treatment arms including MRTX1133 IP twice daily, gemcitabine treatment every 3 days and (n)ab-paclitaxel on days 13 and 19, or a combination of MRTX1133 and gemcitabine/(n)ab-paclitaxel (GnP). F, Percentage of mice within each treatment group presenting with metastasis (n = 9–11 mice per group). Significance determined by Fisher’s exact test and adjusted with Benjamini-Hocheberg correction. Only significant pairwise comparisons are labeled with a P value (P value ≤ 0.05). G, Experimental workflow to study the effect of GnP, MRTX1133, or combination of both on established metastases from 6694C2 and 6694C2-LM cell lines. H, Barplot depicting the total number of lung macrometastases from 6694C2 (left) or 6694C2-LM (right) across treatment groups (n = 5–10 mice per cell line and treatment). Significance determined via Kruskal–Wallis test followed by Dunn’s test and adjusted with Benjamini–Hochberg correction. Only the significant P values are displayed (P value ≤ 0.05).
Figure 6. Enhanced efficacy of combination treatment with KrasG12D inhibition and chemotherapy in primary and metastatic PDAC. A, Tumor growth kinetics (as measured by ultrasound) of 6694C2 orthotopic pancreatic tumors in C57BL6/J mice treated with the indicated regimens. Comparisons have been done at the endpoint of vehicle treated mice against all other arms (day 28, timepoint 1); and at day 52 for MRTX1133 and MRTX1133/GnP compared to GnP alone (timepoint 2). Significance determined with two-way ANOVA with the Šidák multiple comparisons test. The adjusted P values for each timepoint and comparison is displayed on the right. B, Immunoblots of the 6694C2 and 6694-LM cell lines treated for 24 hours with the indicated doses of MRTX1133. GAPDH was used as protein loading control. C, MRTX1133 dose-response curves for 6694C2 and 6694C2-LM cell lines treated with increasing concentration of MRTX1133 for 5 days. Points are the mean ± SEM of three biological replicates. Significance determined by two-sided Student t test between AUCs from three biological replicates from each cell line. D, Vehicle and MRTX1133 treatment of animals bearing syngeneic subcutaneous double flank tumors of 6694C2 or 6694C2-LM. Points are the mean ± SEM (n = 5 double flanked mice per cell line and treatment). Significance determined by Brown–Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test. E, Overview of the metastatic model. Subcutaneous 6694C2-LM tumors are surgically resected, and mice are monitored for lung metastasis. Adjuvant treatment schedule is shown, with treatment arms including MRTX1133 IP twice daily, gemcitabine treatment every 3 days and (n)ab-paclitaxel on days 13 and 19, or a combination of MRTX1133 and gemcitabine/(n)ab-paclitaxel (GnP). F, Percentage of mice within each treatment group presenting with metastasis (n = 9–11 mice per group). Significance determined by Fisher’s exact test and adjusted with Benjamini-Hocheberg correction. Only significant pairwise comparisons are labeled with a P value (P value ≤ 0.05). G, Experimental workflow to study the effect of GnP, MRTX1133, or combination of both on established metastases from 6694C2 and 6694C2-LM cell lines. H, Barplot depicting the total number of lung macrometastases from 6694C2 (left) or 6694C2-LM (right) across treatment groups (n = 5–10 mice per cell line and treatment). Significance determined via Kruskal–Wallis test followed by Dunn’s test and adjusted with Benjamini–Hochberg correction. Only the significant P values are displayed (P value ≤ 0.05).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

28 Valid · 0 Not valid · 6 Not checked · 168 Own results and interpretations

104 more claims · 7 with their cited sources checked

Create a free account to see all 202 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 68
  • Probably not a substantial claim. 32
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 100 references

Cited by

See all 308

Metadata

Authors
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., Uribe, G. A., Yang, A., Kapner, K. S., Hambitzer, F. P., Qiang, L., Feng, H., Geisberg, J., Wang, J., Evans, K. E., Lyu, H., Schalck, A., Feng, N., Lopez, A. M., Bristow, C. A., Kim, M. P., Rajapakshe, K. I., Bahrambeigi, V., Roth, J. A., Garg, K., Guerrero, P. A., Stanger, B. Z., Cristea, S., Lowe, S. W., Baslan, T., Van Allen, E. M., Mancias, J. D., Chan, E., Anderson, A., Katlinskaya, Y. V., Shalek, A. K., Hong, D. S., Pant, S., Hallin, J., Anderes, K., Olson, P., Heffernan, T. P., Chugh, S., Christensen, J. G., Maitra, A., Wolpin, B. M., Raghavan, S., Nowak, J. A., Winter, P. S., Dougan, S. K., & Aguirre, A. J.
Affiliations
  • Broad Institute (US)
  • Harvard University (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Dana-Farber Cancer Institute (US)
  • 3Harvard Medical School, Boston, Massachusetts.
  • 8Exact Sciences, Redwood City, California.
  • University of Pennsylvania (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Amgen (United States) (US)
  • Mirati Therapeutics (United States) (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Aguirre, Andrew J.
Venue
Cancer Discovery
Published
2024-07-05
Volume
14
Issue
11
Pages
2135-2161
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4400416998
Cited by
308
References
100
Citations by year
2026: 162 · 2025: 129 · 2024: 17
FWCI
54.57
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • Break Through Cancer
  • National Cancer Institute (R01 CA276268, U01 CA274276, P50CA127003, P50CA221707, R01CA218230)
  • Hale Family Center for Pancreatic Cancer Research
  • Lustgarten Foundation
  • Pancreatic Cancer Action Network
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
KRAS inhibition, acquired drug resistance, pancreatic ductal adenocarcinoma, KRAS G12C, KRAS G12D, adagrasib, sotorasib, MRTX1133, PIK3CA mutation, PI3K/AKT/mTOR pathway, epithelial-mesenchymal transition, KPC mouse model, organoid models, combination therapy, chemotherapy, YAP, c-Myc, CDK6, non-genetic resistance, drug resistance mechanisms
MeSH terms
Animals, Humans, Mutation, Pancreatic Neoplasms, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-24-0177
The paper
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., Uribe, G. A., Yang, A., Kapner, K. S., Hambitzer, F. P., Qiang, L., Feng, H., Geisberg, J., Wang, J., Evans, K. E., . . . Aguirre, A. J. (2024). Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-24-0177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.